MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

Grifols SA

Затворен

СекторФинансови

10.28 0.19

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.245

Максимум

10.345

Ключови измерители

By Trading Economics

Приходи

17M

69M

Продажби

183M

2B

P/E

Средно за сектора

42

24.968

EPS

0.088

Марж на печалбата

3.491

Служители

23,800

EBITDA

57M

482M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+16.62% upside

Дивиденти

By Dow Jones

Следващи печалби

29.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

2.4B

6B

Предишно отваряне

10.09

Предишно затваряне

10.28

Настроения в новините

By Acuity

35%

65%

132 / 538 Класиране в Finance

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Grifols SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.04.2025 г., 17:19 ч. UTC

Придобивния, сливания и поглъщания

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2.04.2025 г., 13:02 ч. UTC

Придобивния, сливания и поглъщания

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2.04.2025 г., 10:13 ч. UTC

Придобивния, сливания и поглъщания

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8.07.2024 г., 10:40 ч. UTC

Придобивния, сливания и поглъщания

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8.07.2024 г., 09:13 ч. UTC

Придобивния, сливания и поглъщания

Grifols Faces Delisting Bid From Founding Family and Brookfield

15.04.2025 г., 09:55 ч. UTC

Пазарно говорене

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Grifols SA Прогноза

Ценова цел

By TipRanks

16.62% нагоре

12-месечна прогноза

Среден 12 EUR  16.62%

Висок 13 EUR

Нисък 11 EUR

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Grifols SA през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

1

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

N/A / 8.566Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

132 / 538 Класиране в Финансови

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.